RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mechanism of PAX6 overexpression in inhibiting the growth of hepatocellular carcinoma cells and promoting the killing ability of the natural killer cells.
Mechanism of PAX6 overexpression in inhibiting the growth of hepatocellular carcinoma cells and promoting the killing ability of the natural killer cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
PAX6 在 HCC 患者血清和肝细胞癌细胞系中表达降低。PAX6 过表达可抑制肝细胞癌细胞生长,增强 NK 细胞对肝癌细胞的杀伤效率。其机制与 PAX6 抑制金属蛋白酶表达及降低 sMICA 和 sULBP2 分泌水平有关。
配对盒基因6(PAX6)在胚胎发育调控中发挥重要作用。PAX6表达异常与多种肿瘤的发生发展相关。PAX6在不同肿瘤中可发挥促癌或抑癌作用。本研究旨在观察PAX6过表达对肝细胞癌细胞生长的影响,以及自然杀伤(NK)细胞对肝细胞癌细胞的杀伤作用及其可能机制。配对盒基因6(PAX6)在胚胎发育调控中发挥重要作用。PAX6表达异常与多种肿瘤的发生发展相关。PAX6在不同肿瘤中可发挥促癌或抑癌作用。本研究旨在观察PAX6过表达对肝细胞癌细胞生长的影响,以及自然杀伤(NK)细胞对肝细胞癌细胞的杀伤作用及其可能机制。
采用ELISA法检测68例肝细胞癌(HCC)患者和10名健康志愿者外周血中PAX6、可溶性主要组织相容性复合体I类相关蛋白A(sMICA)和可溶性UL16结合蛋白2(sULBP2)的蛋白水平。在37 ℃、5% CO₂条件下体外培养肝细胞癌细胞系(HepG2、LM3)和人正常肝细胞(LO2)。将PAX6过表达质粒(PAX6-OE)和空载体(NC)转入HepG2和LM3细胞,构建稳定细胞系。分别采用实时PCR、Western blotting和免疫荧光法检测HepG2和LM3细胞中PAX6的mRNA和蛋白表达水平。在HepG2和LM3细胞中过表达PAX6后,采用CCK-8法和细胞划痕实验检测细胞生长和迁移能力,采用ELISA法检测上清液中sMICA和sULBP2的水平。采用Western blotting法检测HepG2和LM3细胞中基质金属蛋白酶2(MMP2)、基质金属蛋白酶9(MMP9)以及解整合素和金属蛋白酶10(ADAM10)。采用流式细胞术检测NK细胞对这两种HCC细胞的杀伤能力。采用ELISA法检测68例肝细胞癌(HCC)患者和10名健康志愿者外周血中PAX6、可溶性主要组织相容性复合体I类相关蛋白A(sMICA)和可溶性UL16结合蛋白2(sULBP2)的蛋白水平。肝细胞
与健康志愿者相比,HCC 患者 PAX6 表达显著降低(P=0.002),而 sMICA 和 sULBP2 表达显著升高(分别为 P=0.004 和 P<0.001)。实时 PCR 和 Western blotting 结果显示,与 LO2 细胞相比,HepG2 和 LM3 细胞中 PAX6 的 mRNA 和蛋白表达显著降低(均 P<0.05)。免疫荧光结果也显示,HepG2 和 LM3 中 PAX6 的表达低于 LO2 细胞。与 NC 组相比,HepG2 和 LM3 细胞的增殖和迁移能力降低(均 P<0.05)。PAX6-OE 组中 HepG2 和 LM3 细胞 MMP2、MMP9 和 ADAM10 的蛋白表达显著降低,且 PAX6-OE 组 HepG2 和 LM3 细胞上清液中 sMICA 和 sULBP2 水平显著低于 NC 组(均 P<0.05)。流式细胞术结果显示,与 NC 组相比,PAX6-OE 组中 NK 细胞杀伤 HepG2 和 LM3 细胞的比例显著增加(均 P<0.05)。
Paired box gene 6 ( PAX6 ) plays a major role in the regulation of embryonic development. Abnormal expression of PAX6 is associated with the development of various tumors. PAX6 can play a role in promoting or suppressing cancer in different tumors. This study aim to observe the effect of overexpression of PAX6 on the growth of hepatocellular carcinoma cells, and the killing of hepatocellular carcinoma cells via natural killer (NK) cell and the possible mechanism.
The protein levels of PAX6, soluble major histocompatibility complex class I-like protein A (sMICA) and soluble UL16 binding protein 2 (sULBP2) in peripheral blood from 68 cases of hepatocellular carcinoma (HCC) patients and 10 healthy volunteers were detected by ELISA. Hepatocellular carcinoma cell line (HepG2, LM3) and human normal liver cells (LO2) were cultured at 37 ℃ and 5% CO 2 condition in vitro. The PAX6 overexpressed plasmid (PAX6-OE) and empty vector (NC) were transferred into HepG2 and LM3 cells to construct stable cell lines. The mRNA and protein expression levels of PAX6 in HepG2 and LM3 cells were detected by real-time PCR, Western blotting and immunofluorescence, respectively. PAX6 was overexpressed in HepG2 and LM3 cells, the cell growth and migration ability were detected by CCK-8 method and cell scratch assay, and the levels of sMICA and sULBP2 in the supernatant were detected by ELISA. Matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9) and disintegrin and metalloproteinase 10 (ADAM10) in HepG2 and LM3 cells were detected by Western blotting. The killing ability of NK cells against these 2 HCC cells was detected by flow cytometry.
Compared with the healthy volunteers, the expressions of PAX6 in the HCC patients were significantly decreased ( P =0.002), while the expression of sMICA and sULBP2 were significantly increased ( P =0.004 and P <0.001, respectively). Real-time PCR and Western blotting results showed that compared with LO2 cells, mRNA and protein expressions of PAX6 in HepG2 and LM3 cells were significantly decreased (all P <0.05). Immunofluorescence results also showed that the expressions of PAX6 in HepG2 and LM3 were lower than those of LO2 cells. Compared with the NC group, the ability of proliferation and migration of HepG2 and LM3 cells were decreased (both P <0.05). The protein expressions of MMP2, MMP9 and ADAM10 in HepG2 and LM3 cells in the PAX6-OE group were significantly decreased, and the levels of sMICA and sULBP2 in superneant of HepG2 and LM3 cells in the PAX6-OE group were significantly lower than those in the NC group (all P <0.05). Flow cytometry results showed that compared with the NC group, the proportion of NK cells killing HepG2 and LM3 cells in PAX6-OE group was significantly increased (both P <0.05).
The expression of PAX6 is decreased in serum of HCC patients and hepatocellular carcinoma cell lines. Overexpression of PAX6 can inhibit the growth of hepatocellular carcinoma cells, enhance the killing efficiency of NK cells against hepatoma cells. The mechanism is related to the inhibition of the expression of metalloproteinase via PAX6 and the decrease of the secretion levels of sMICA and sULBP2.
Paired box gene 6 ( PAX6 ) plays a major role in the regulation of embryonic development. Abnormal expression of PAX6 is associated with the development of various tumors. PAX6 can play a role in promoting or suppressing cancer in different tumors. This study aim to observe the effect of overexpression of PAX6 on the growth of hepatocellular carcinoma cells, and the killing of hepatocellular carcinoma cells via natural killer (NK) cell and the possible mechanism.
The protein levels of PAX6, soluble major histocompatibility complex class I-like protein A (sMICA) and soluble UL16 binding protein 2 (sULBP2) in peripheral blood from 68 cases of hepatocellular carcinoma (HCC) patients and 10 healthy volunteers were detected by ELISA. Hepatocellular
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。